IMPAACT 2036

Phase I/II Study of the Safety, Tolerability, Pharmacokinetics, and antiviral activity of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed HIV-Infected

Co-HED

This trial aims to assess the effects of co-administration of Highly Active Anti-retroviral therapy (HAART) and Antiepileptic drugs on

P1115

A multi-centre phase I/II proof-of-concept clinical trial exploring the effects of early intensive antiretroviral therapy (ART) on achieving HIV remission in neonates. Started in June 2015 at Baylor-Uganda’s Centre of […]